GAITHERSBURG, Md., Nov. 2, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its third quarter 2023 financial results and operational highlights at 8:30 a.m. Eastern Standard Time (EST) on Thursday, November 9, 2023. Details of the event and replay are as follows:
Conference call details: | |
Date: | November 9, 2023 |
Time: | 8:30 a.m. U.S. EST |
Dial-in number: | (877) 550-1858 (Domestic) or (848) 488-9160 (International) |
Passcode: | 1754341 |
Webcast: |
Replay details: | |
Date: | Available starting at 11:30 a.m. EST, November 9, 2023, until |
Dial-in number: | (800) 645-7964 (Domestic) or (757) 849-6722 (International) |
Passcode: | 5567# |
Webcast: | ir.novavax.com/events, until February 7, 2024 |
About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. Focused on the world's most urgent health challenges, Novavax is currently evaluating vaccines for COVID-19, influenza and COVID-19 and influenza combined. Please visit novavax.com and LinkedIn for more information.
Contacts:
Investors
Erika Schultz
240-268-2022
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media
Ali Chartan
240-720-7804
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$4.93 |
| Daily Change: | 0.22 4.67 |
| Daily Volume: | 4,598,069 |
| Market Cap: | US$689.950M |
April 15, 2024 February 28, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
